Cohance Lifesciences Ltd
NSE:COHANCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cohance Lifesciences Ltd
NSE:COHANCE
|
IN |
|
S
|
Silicon 2 Co Ltd
KOSDAQ:257720
|
KR |
|
C
|
CIMC Enric Holdings Ltd
HKEX:3899
|
CN |
Cohance Lifesciences Ltd
Cohance Lifesciences Ltd. manufactures chemical products. The company is headquartered in Rangareddi, Telangana and currently employs 1,212 full-time employees. The company went IPO on 2020-03-09. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Cohance Lifesciences Ltd. manufactures chemical products. The company is headquartered in Rangareddi, Telangana and currently employs 1,212 full-time employees. The company went IPO on 2020-03-09. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Revenue Outlook Cut: Cohance Lifesciences reduced its FY '26 revenue outlook to an early to mid-double-digit decline due to timing and portfolio mix challenges.
Q3 and 9M Revenue Decline: Revenue fell 19.5% YoY in Q3 and 6.7% YoY for the first nine months, impacted by destocking, regulatory issues, and demand delays.
Margins Under Pressure: Gross margin improved YoY for nine months but fell in Q3. Adjusted EBITDA margin dropped sharply to 21% (9M) and 15.5% (Q3) due to lower high-margin product mix and operating deleverage.
Transition Year: Management characterized FY '26 as a transition year due to product timing, customer delays, and patent expiries, but stressed these are not structural issues.
FY '27 Growth Reaffirmed: Despite short-term headwinds, management expects a return to growth in FY '27, especially in API+ and CDMO segments.
No Customer Loss: Management emphasized that no customers or orders were lost during the period, and customer engagement remains strong.
Specialty Chemicals Outperformance: Specialty Chemicals revenue grew 32% YoY in nine months, supported by new customer wins and pipeline development.
